Applied Microbiology and Biotechnology

, Volume 93, Issue 3, pp 1031–1040 | Cite as

Development of a measles vaccine production process in MRC-5 cells grown on Cytodex1 microcarriers and in a stirred bioreactor

  • Khaled Trabelsi
  • Samy Majoul
  • Samia Rourou
  • Héla KallelEmail author
Biotechnological products and process engineering


Measles vaccination remains the most efficient way to control the spread of the virus. This work focuses on the production of a measles vaccine using stirred conditions as an advanced option for process scale up. Non-porous Cytodex 1 microcarriers were used to support MRC-5 cell growth in suspension cultures. Virus replication was first optimized in spinner flasks, and the effects of various operational parameters were investigated. Cell infection with AIK-C measles strain at an MOI (multiplicity of infection) of 0.005, without glucose regulation and in M199 medium, resulted in a virus titer of 106.25 TCID50 (median tissue culture infective dose)/ml. To optimize the production process in a 7-l bioreactor, we carried out various perfused cultures using minimum essential medium (MEM) + 5% FCS diluted with phosphate-buffered saline (PBS). We achieved a high cell density level (4.1 × 106 cells/ml) with an efficient use of the medium when MEM + 5% FCS diluted with PBS at 25% was used during the cell amplification step. Optimization of measles production in MRC-5 cells grown on Cytodex 1 beads in a 7-l bioreactor showed that perfusion was the most efficient when compared to repeated-batch culture. Perfusion at a rate of 0.25 V (reactor volume)/day showed the highest specific productivity (1.6 IVP [infectious virus particle] cell−1 day−1). Testing of several stabilizers containing pharmaceutically improved components such as sugars, amino acids, and charged ions showed that the formulation composed of sucrose and MgCl2, led to the maintenance of the infectivity of the AIK-C measles virus strain to a significant level, when stored at +28 °C, +4 °C and −60 °C.


MRC-5 cells Cytodex 1 microcarriers Stirred bioreactor AIK-C measles strain Measles vaccine 


  1. Audsley JM, Tannock GA (2005) The growth of attenuated influenza vaccine donor strains in continuous cell lines. J Virol Methods 2:187–193CrossRefGoogle Scholar
  2. Aunins JG, Bader B, Caola A, Griffiths J, Katz M, Licari P, Ram K, Ranucci CS, Zhou W (2003) Fluid mechanisms, cell distribution and environment in cellcube bioreactors. Biotechnol Prog 19:2–8CrossRefGoogle Scholar
  3. Aunins JG (2000) Viral vaccine production in cell culture. In: Spier ER (ed) Encyclopedia of cell technology. Wiley, New York, pp 1183–1207Google Scholar
  4. Bautista-Lopez N, Ward BJ, Mills E, McCornick D, Martel N, Ratnam S (2000) Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. Vaccine 18:1393–1401CrossRefGoogle Scholar
  5. Brandau DT, Jones LS, Wiethoff CM, Rexroad J, Middaugh CR (2003) Thermal stability of vaccines. J Pharm Sci 92:218–231CrossRefGoogle Scholar
  6. Butler M (1987) Growth limitations on microcarriers. Adv Biochem Eng Biotechnol 34:57–84Google Scholar
  7. Cutts FT, Clements CJ, Bennett JV (1997) Alternative routes of measles immunization: a review. Biologicals 25:323–338CrossRefGoogle Scholar
  8. Erk I, Huet J, Duarte M, Duquerroy S, Rey F, Cohen J, Lepault J (2003) A zinc ion controls assembly and stability of the major capsid protein of rotavirus. J Virol 6:3535–3601Google Scholar
  9. Genzel Y, Fischer M, Reichl U (2006) Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture. Vaccine 24:3261–3272CrossRefGoogle Scholar
  10. Griffin DE, Pan CH (2009) Measles: old vaccines, new vaccines. In: Griffin DE, Oldstone MBA (eds) Measles—Pathogenesis and control. Springer, Berlin, pp 191–212Google Scholar
  11. Griffin DE, Bellini WJ (2001) Measles virus. In: Knipe DM, Howley PM (eds) Fields virology, 4th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1267–1312Google Scholar
  12. Griffin DE (1995) Immune response during measles virus infection. Curr Trop Microbiol Immunol 191:117–134CrossRefGoogle Scholar
  13. Lang J, Cetre JC, Picot N, Lanta M, Briantais P, Vital S, Le Mener V, Lutsch C, Rotivel Y (1998) Immunogenicity and safety in adults of a new chromatographically purified Vero-cell rabies vaccine (CPRV): a randomized, double-blind trial with purified Vero-cell rabies vaccine (PVRV). Biologicals 4:299–308CrossRefGoogle Scholar
  14. Kissman J, Salvador FA, Rudolph A, Braun C, Cape SP, Sievers RE, Federspiel MJ, Joshi SB, Middaugh CR (2008) Stabilization of measles virus for vaccine formulation. Hum Vaccines 4:350–359CrossRefGoogle Scholar
  15. Kuno-Sakai H, Kimura M (2003) Removal of gelatin from live vaccines and DTaP—an ultimate solution for vaccine-related gelatin allergy. Biologicals 4:245–249CrossRefGoogle Scholar
  16. Maranga L, Brazão TF, Carrondo MJ (2003) Virus-like particle production at low multiplicities of infection with the baculovirus insect cell system. Biotechnol Bioeng 2:245–253CrossRefGoogle Scholar
  17. Moss WJ, Griffin DE (2006) Global measles elimination. Nat Rev Microbiol 12:900–908CrossRefGoogle Scholar
  18. Montagnon B, Vincent-Falquet JC, Fanget B (1984) Thousand liter scale microcarrier culture of Vero cells for killed polio virus vaccine. Dev Biol Stand 55:37–42Google Scholar
  19. Nechaeva EA, Kashentseva EA, Agafonov AP, Varaksin NA, Ryabicheva TG, Konstantinov AP, Bondarenko VN, Kolokoltsova TD, Kits IV, Senkina TY, Zhilina NV (1998) New form of the live measles vaccine for oral administration. In: Merten OW, Perrin P, Griffiths B (eds) New developments and new applications in animal cell technology. Kluwer Academic Publishing, Dordrecht, pp 573–575Google Scholar
  20. Nkrumah FK, Osei-Kwasi M, Dunyo SK, Koram KA, Afari EA (1998) Comparison of AIK-C measles vaccine in infants at 6 months with Schwarz vaccine at 9 months: a randomized controlled trial in Ghana. WHO Bull 76:353–359Google Scholar
  21. Ohtake S, Martin RA, Yee L, Chen D, Kristensen DD (2010) Heat stable measles vaccine produced by spray drying. Vaccine 28:1275–1284CrossRefGoogle Scholar
  22. Radlett PJ (1987) The use of BHK suspension cells for the production of foot and mouth disease vaccines. Adv Biochem Eng Biotechnol 34:129–146Google Scholar
  23. Shirley JA, Beards GM, Thouless ME, Flewett TH (1981) The influence of divalent cations on the stability of human rotavirus. Arch Virol 1:1–9CrossRefGoogle Scholar
  24. Sidorenko ES, Dorofeeva LV, Kaptsova TI, Steinberg LL, Zasorina IN, Sinitsyna OA, Boriskin YS (1989) Experimental-scale measles and mumps vaccine production on microcarrier-grown cells. Vaccine 7:554–556CrossRefGoogle Scholar
  25. Tidjani O, Grunitsky B, Guerin N, Levy-Bruhk D, Lecam N, Xuereff C, Tatagen K (1989) Serological effects of Edmonston-Zagreb, Schwarz and AIK-C measles vaccine strains given at ages 4–5 or 8–10 months. Lancet 2:1357–1360CrossRefGoogle Scholar
  26. Turnbull AE, Skulimowski A, Smythe JA, Alexander IE (2000) Adenoassociated virus vectors show variable dependence on divalent cations for thermostability: implications for purification and handling. Hum Gene Therapy 4:629–635CrossRefGoogle Scholar
  27. Trabelsi K, Rourou S, Loukil H, Majoul S, Kallel H (2006) Optimization of virus yield as a strategy to improve rabies vaccine production by Vero cells in a bioreactor. J Biotechnol 121:261–271CrossRefGoogle Scholar
  28. Trabelsi K, Rourou S, Loukil H, Majoul S, Kallel H (2005) Comparison of various culture modes for the production of rabies virus by Vero cells grown on microcarriers in a 2-l bioreactor. Enzyme Microb Biotechnol 36:514–519CrossRefGoogle Scholar
  29. Tree JA, Richardson C, Fooks AR, Clegg JC, Looby D (2001) Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 25–26:3444–3450CrossRefGoogle Scholar
  30. Warnock JN, Al-Rubeai M (2006) Bioreactor systems for the production of biopharmaceuticals from animal cells. Biotechnol Appl Biochem 45:1–12CrossRefGoogle Scholar
  31. Wolfson LJ, Strebel PM, Gacic-Dobo M, Hockstra EJ, McFarland JW, Hersh BS (2007) Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 369:191–200CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Khaled Trabelsi
    • 1
  • Samy Majoul
    • 1
  • Samia Rourou
    • 1
  • Héla Kallel
    • 1
    Email author
  1. 1.Viral Vaccines Research and Development UnitInstitute Pasteur de TunisTunis BelvédèreTunisia

Personalised recommendations